Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR) represent one of the first targeted therapies to demonstrate efficacy in CRC, both as a monotherapy and in combination with cytotoxic chemotherapy [19]. Here, EGFR is linked to colorectal carcinoma.